B cells and transplantation tolerance (Q37782255)

23 August 2017

title

B cells and transplantation tolerance (English)

1 reference

23 August 2017

Allan D. Kirk

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20736924

22 June 2024

Nicole A. Turgeon

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20736924

22 June 2024

Neal N. Iwakoshi

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20736924

22 June 2024

language of work or name

English

0 references

publication date

24 August 2010

1 reference

full work available at URL

23 August 2017

http://www.nature.com/articles/nrneph.2010.111.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2010.111

http://www.nature.com/articles/nrneph.2010.111

22 June 2024

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2010.111

Nature Reviews Nephrology

22 June 2024

published in

1 reference

23 August 2017

1 reference

23 August 2017

1 reference

23 August 2017

page(s)

584-593

1 reference

Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

ERK signaling is a molecular switch integrating opposing inputs from B cell receptor and T cell cytokines to control TLR4-driven plasma cell differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Tolerance through indifference: autoreactive B cells to the nuclear antigen La show no evidence of tolerance in a transgenic model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Mechanism of action of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Roles of deletion and regulation in creating mixed chimerism and allograft tolerance using a nonlymphoablative irradiation-free protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

A critical precursor frequency of donor-reactive CD4+ T cell help is required for CD8+ T cell-mediated CD28/CD154-independent rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

New treatments for acute humoral rejection of kidney allografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Humoral rejection of organ allografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Significance of donor-specific antibodies in acute rejection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Diagnostic value of C4d in renal biopsies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Antibody-mediated organ-allograft rejection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Mechanisms of alloantibody production in sensitized renal allograft recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Kidney transplantation: mechanisms of rejection and acceptance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

The role of B cells and alloantibody in the host response to human organ allografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Cellular and genetic mechanisms of self tolerance and autoimmunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Sites and stages of autoreactive B cell activation and regulation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Does immunological tolerance explain the waste in the B-lymphocyte immune system? Experiment and theory

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Receptor editing in lymphocyte development and central tolerance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Receptor editing in a transgenic mouse model: site, efficiency, and role in B cell tolerance and antibody diversification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Predominant autoantibody production by early human B cell precursors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Elimination of self-reactive B lymphocytes proceeds in two stages: arrested development and cell death.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Enforced Bcl-2 expression inhibits antigen-mediated clonal elimination of peripheral B cells in an antigen dose-dependent manner and promotes receptor editing in autoreactive, immature B cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

CD40 inhibits B cell apoptosis by upregulating bcl-xL expression and blocking oxidant accumulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

The control of apoptosis in lymphocyte selection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

31 March 2020

Cracking the BAFF code.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Receptor editing in self-reactive bone marrow B cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Receptor editing: an approach by autoreactive B cells to escape tolerance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Contribution of Receptor Editing to the Antibody Repertoire

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

31 March 2020

12 December 2020

In vivo assessment of the relative contributions of deletion, anergy, and editing to B cell self-tolerance

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Cellular mechanisms of self-tolerance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Induction of self-tolerance in mature peripheral B lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Immunoglobulin signal transduction guides the specificity of B cell-T cell interactions and is blocked in tolerant self-reactive B cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Identification of anergic B cells within a wild-type repertoire.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Peripheral deletion of self-reactive B cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

A selective defect in IgM antigen receptor synthesis and transport causes loss of cell surface IgM expression on tolerant B lymphocytes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Mechanisms and meaning of B-lymphocyte tolerance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

BAFF and the plasticity of peripheral B cell tolerance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Tonic B cell antigen receptor signals supply an NF-kappaB substrate for prosurvival BLyS signaling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Manipulating B cell homeostasis: a key component in the advancement of targeted strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Antidonor antibodies and transplantation: how to deal with them before and after transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Treatment of humoral rejection with rituximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Rituximab as treatment for refractory kidney transplant rejection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Overcoming a positive crossmatch in living-donor kidney transplantation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Signal integration in the endoplasmic reticulum unfolded protein response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Abrogation of anti-HLA antibodies via proteasome inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Transplant tolerance in non-human primates: progress, current challenges and unmet needs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Crossing the bridge: large animal models in translational transplantation research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Organ transplantation--how much of the promise has been realized?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Immune tolerance: mechanisms and application in clinical transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

IMMUNOGENETIC CONSEQUENCES OF VASCULAR ANASTOMOSES BETWEEN BOVINE TWINS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Actively acquired tolerance of foreign cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Self tolerance to human A and B histo-blood group antigens exists at the B cell level and cannot be broken by potent polyclonal B cell activation in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Developmental patterns of ABO isoagglutinins in normal children correlated with the effects of age, sex, and maternal isoagglutinins.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

ABO-incompatible heart transplantation in infants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Targeting antibody-mediated rejection in the setting of ABO-incompatible infant heart transplantation: graft accommodation vs. B cell tolerance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Liver transplantation across ABO blood group barriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

ABO-incompatible kidney transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Characterization of mixed allogeneic chimeras. Immunocompetence, in vitro reactivity, and genetic specificity of tolerance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

HLA-mismatched renal transplantation without maintenance immunosuppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Humoral theory of transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Prope tolerance: the future of organ transplantation--from the laboratory to the clinic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

The use of Campath-1H as induction therapy in renal transplantation: preliminary results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

CAMPATH IH ALLOWS LOW-DOSE CYCLOSPORINE MONOTHERAPY IN 31 CADAVERIC RENAL ALLOGRAFT RECIPIENTS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Alemtuzumab (Campath-1H) in kidney transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Campath-1H in renal transplantation: The University of Wisconsin experience.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Steroid-free tacrolimus monotherapy after pretransplantation thymoglobulin or Campath and laparoscopy in living donor renal transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Homeostatic control of B lymphocyte subsets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

The BLyS family: toward a molecular understanding of B cell homeostasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Signalling crosstalk in B cells: managing worth and need

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

BAFF is increased in renal transplant patients following treatment with alemtuzumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Thymus-marrow cell combinations. Synergism in antibody production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Cell to cell interaction in the immune response. I. Hemolysin-forming cells in neonatally thymectomized mice reconstituted with thymus or thoracic duct lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Co-stimulatory blockade in the treatment of murine systemic lupus erythematosus (SLE).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Treatment of murine lupus with CTLA4Ig

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Costimulation blockade in autoimmunity and transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

What's next in the pipeline

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Costimulatory pathways in transplantation: challenges and new developments.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Identification of a B cell signature associated with renal transplant tolerance in humans.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.111

Mechanism of action of rituximab

31 March 2020

1 reference

12 December 2020

Spotlight on alemtuzumab.

1 reference

12 December 2020

IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)

1 reference

12 December 2020

Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab

1 reference

12 December 2020

Journal of Clinical Investigation

109

119

2052

JL Jones

2009

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2010.111

22 June 2024

Identifiers

1 reference

23 August 2017

1 reference